Status and phase
Conditions
Treatments
About
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic MYBPC3 mutation-associated nonobstructive hypertrophic cardiomyopathy (nHCM).
Full description
The study will consist of 2 escalating dose cohorts. The study will enroll at least 6 and as many as 15 patients. All patients will receive active drug. The study will follow patients for 5 years following a single dose of TN-201.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
15 participants in 2 patient groups
Loading...
Central trial contact
Laura Robertson, M.D.; LaTanya Tomlinson, RN, MHSA
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal